SLNO - CIK 0001484565
The table below shows SOLENO THERAPEUTICS INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $25.98M | -$32.75M | -$12.53M | -$6.73M | -$6.36M | -$7.49M |
| Capital expenditure | $40.00K | $5.00K | $11.00K | $0.00 | - | $4.00K |
| Investing cash flow | $37.98M | $22.94M | -$115.24M | $0.00 | - | -$4.00K |
| Dividends paid | - | - | - | - | - |
SOLENO THERAPEUTICS INC reported operating cash flow of $46.80M for fiscal year 2025. That is up 167.7% from -$69.10M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$13.50M (FY 2016) to $46.80M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $4.00K | $0.00 | - | - | - | - |
| Financing cash flow | -$1.04M | $3.22M | $938.00K | $0.00 | $14.03M | -$125.00K |